Prof Christos Markopoulos (National and Kapodistrian University of Athens, Athens, Greece) and Prof Giuseppe Curigliano (European Institute of Oncology, Milan, Italy) discuss the RxPONDER trial and its impact on best clinical practice.
Initially, Prof Markopoulos gives an introduction of Oncotype DX. The participants then discuss targeting chemotherapy treatment to only patients who would derive a benefit from it. Prof Curigliano says that not all patients benefit from Chemotherapy.
They then discuss the results of TAILORx trial, Oxford Overview and SWOG-8814 study. Prof Curigliano touches upon the method of the RxPONDER trial. They explain the results from this trial and discuss what is new from the 2021 RxPONDER presentation.
Prof Markopoulos and Prof Curigliano conclude by talking about how the RxPONDER trial should impact clinical practice.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
Негізгі бет Ғылым және технология The RxPONDER trial and its impact on best clinical practice
Пікірлер